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sentative sample of Medicare beneﬁciaries. METHODS: This
study used data from the 2003 Medicare Current Beneﬁciary
Survey (MCBS), a continuous national sample of approximately
12,000 persons. Study patients were 65+ years old, eligible for
Medicare Parts A and B, and community residents. The COPD
cohort comprised patients with 1+ medical claim(s) with a
COPD diagnosis (ICD-9-CM codes: 491.xx, 492.x, 496). The
comparison cohort included non-COPD patients, with at least
one medical claim, matched 1:1 based on age, sex, race, and edu-
cation level. The study measures included self-rated general
health status, self-reported medical conditions, impairment in
activities of daily living (ADLs) and instrumental activities of
daily living (IADLs). RESULTS: A total of 1219 patients were
identiﬁed for the COPD cohort, all of whom were matched to
comparison cohort patients (mean age ± SD: 76 ± 7; 50%
female). COPD patients reported poorer general health (43%
reported “fair” or “poor” health versus 22% among controls; P
< 0.001) and more chronic medical conditions (mean of 4.2
versus 3.2 for controls; P < 0.001). COPD patients were also sig-
niﬁcantly (P < 0.001) more likely to report difﬁculties in per-
forming one or more ADLs (46% versus 28%) or IADLs (42%
versus 26%). For the COPD cohort, the most common ADL lim-
itations were difﬁculty walking (42%) and transferring from a
bed or chair (20%), while the most common IADL limitations
were difﬁculty doing heavy housework (42%) and shopping
(17%). CONCLUSION: In this community-residing Medicare
population, COPD patients reported poorer health and had
greater impairment in functioning than those without COPD.
These results have implications for improving COPD manage-
ment in the Medicare population.
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OBJECTIVES: Economic beneﬁts of early initiation of inhaled
corticosteroids (ICS) treatment in patients diagnosed with
Chronic Obstructive Pulmonary Disease (COPD) were assessed
using a large managed care claims database. METHODS: Early
initiation was deﬁned as beginning ICS within three months of
initiation of regular bronchodilators and was compared with
patients who initiated ICS therapy thereafter. To avoid biases due
to the treatment selection, a propensity-score-matching tech-
nique was used. Exacerbation risks and other resource utiliza-
tion per person-year were compared between the two groups. A
two-part model with multivariate logistic and generalized linear
model (GLM) regression was used to estimate differences in
medical, pharmacy, and total service costs. RESULTS: A total of
7712 matched COPD patients with comparable background
characteristics were identiﬁed. Early initiation of ICS was asso-
ciated with lower exacerbation risks and resource utilization.
Patients who started ICS within three months had more ICS pre-
scriptions (3.7 vs. 2.4 prescriptions per year) and higher phar-
macy costs ($4077 vs. $3868: mean difference +$209, p < 0.05).
However, because of lower medical services use, early initiation
of ICS could save medical costs ($13,837 vs. $14,925: mean dif-
ference −$1.089; p < 0.05) and total costs ($17,994 vs. $18,883:
mean difference −$889; p < 0.05). The same trends were
observed for services directly attributable to COPD conditions.
CONCLUSION: Initiating ICS earlier than the current clinical
guideline recommendation may be beneﬁcial to avoid exacerba-
tions and reduce treatment costs.
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OBJECTIVES: Gastrointestinal Stromal Tumours (GIST) are
rare cancers that generate high expenditures in the Mexican
Health System. The purpose of the study was to model the eco-
nomic and health consequences of second-line treatments (pre-
vious imatinib 400 mg/day failure) in adult patients with GIST
in advanced stages within the Social Security Mexican Institute.
METHODS: A cost–effectiveness analysis was developed using
a Markov modeling approach. The model simulates costs and
effectiveness outcomes in a ﬁve-year period. The model aimed 
to compare sunitinib 50 mg/day, imatinib 800 mg/day and local
best supportive care (BSC) as second-line treatments. Transition
probabilities of the Markov model were obtained according to
clinical trials previously published in the literature. Effectiveness
measures were the number of progression-free-months (PFM)
and life-years gained (LYG). The analysis was conducted from
the health care payer’s perspective (only direct medical costs were
used). Resource use and costs data was obtained from hospital
records at Hospital de Oncología CMN “Siglo XXI” in Mexico
City (n = 12). Both costs and health outcomes were discounted
using a 3% annual rate. Probabilistic sensitivity analysis was per-
formed and acceptability curves were constructed. RESULTS:
Second line treatment with imatinib showed the highest expected
costs (US$37,197.8 ± 1368.8) followed by sunitinib
(US$16,641.0 ± 368.6) and BSC (US$1900.7 ± 404.2). On the
other hand, the best clinical outcomes were obtained by suni-
tinib in both PFM and LYG (5.64 months, 1.4 years) followed
by imatinib (5.28 months, 1.3 years) and BSC (2.52 months, 1.1
years). Imatinib option resulted dominated by sunitinib and the
ICER between sunitinib and BSC was of US$49,134.3 per LYG.
Results were robust to Monte Carlo second order sensitivity
analysis and acceptability curves showed the same results. CON-
CLUSION: In Mexico, sunitinib second-line treatment was the
most cost—effective alternative compared to imatinib. These
results should be taken into account by Mexican decision makers
in the management of patients with GIST.
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OBJECTIVES: Colorectal cancer is the second most commonly
diagnosed cancer and the third cause of cancer-related mortality
in Taiwan. Capecitabine, an oral ﬂuoropyrimidine, is an effec-
tive alternative to intravenous ﬂuorouracil plus leucovorin (5-
FU/LV) in adjuvant treatment of stage III colon cancer. The
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objective of this pharmacoeconomic analysis is to access the cost-
effectiveness of capecitabine compared to 5-FU/LV in the adju-
vant setting in Taiwan from the payer’s [Bureau of National
Health Insurance (BNHI)] perspective. METHODS: A state-
transition economic model was developed to estimate incremen-
tal cost impact and the effectiveness in terms of quality-adjusted
life months (QALMs). Clinical outcomes and medical resource
utilization were collected during the phase III X-ACT study.
Direct medical costs associated with chemotherapy drugs, physi-
cian consultations, and adverse events (AEs) management were
based on Taiwan’s National Health Insurance fee schedule. Intra-
venous chemotherapy administration costs and post-treatment
costs were estimated from an expert panel survey conducted
among 12 colorectal surgeons and medical oncologists. Health-
related utility scores were obtained from published literature.
Outcomes and future costs were discounted at 1.5% and 6%
respectively. Sensitivity analyses were performed on key model
parameters. RESULTS: Administration of capecitabine required
fewer physician visits per patient (7.4 versus 28.0 with 5-FU/LV).
Drug acquisition costs of capecitabine were higher than 5-FU/LV,
however, these cost increments were offset by the chemotherapy
administration cost of 5-FU/LV. In addition, more expensive
medications and longer hospitalization were needed to manage
5-FU/LV-related AEs. As a result, capecitabine demonstrated a
signiﬁcant overall cost savings of $104,546 NTD. Over a life-
time, the survival beneﬁt for capecitabine extends to 9 QALMs.
Capecitabine remained dominant under sensitivity testing. CON-
CLUSION: From a Taiwan BNHI perspective, this pharma-
coeconomic analysis showed that the use of capecitabine in
adjuvant treatment of colon cancer would not only save direct
medical costs but also improve health outcomes compared to 
5-FU/LV.
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OBJECTIVES: With 60 months of follow-up data now available
from the IRIS trial, we updated our previous cost-effectiveness
analysis of ﬁrst-line imatinib versus interferon-á plus cytarabine
(IFN) in newly diagnosed patients with chronic myeloid
leukemia in the chronic phase that was originally based on a
median of 19 months of follow-up. METHODS: We used the
empirical 60-month data from IRIS for patients randomized to
imatinib to calibrate the survival curves generated with the cost-
effectiveness model. Due to the high rate of crossover among
patients randomized to IFN in IRIS, we relied on historical data
to model survival estimates for patients treated with IFN. We
updated costs to 2006 values and applied two sets of costs to
imatinib and IFN: average wholesale prices (AWP) and whole-
sale acquisition costs (WAC). RESULTS: Survival at 5 years for
patients randomized to imatinib was better than predicted with
our original model (89.4% vs. 83.2%). After model calibration,
we estimated remaining life expectancy for ﬁrst-line imatinib
patients to be 19.1 years, an increase of 3.8 years over the orig-
inal model. Remaining quality-adjusted life-years (QALYs) were
estimated at 15.2, an increase of 3.1 QALYs. Estimates for
patients randomized to IFN were maintained at 9.1 years and
6.3 QALYs. With AWPs, ICERs ranged from $40,300 to
$57,100 per QALY when applying less and more conservative
assumptions about the duration of ﬁrst- and second-line treat-
ment with imatinib and IFN. With WACs, ICERs ranged from
$33,500 to $46,100 per QALY. CONCLUSION: Although our
analysis revealed that our initial survival estimates were conser-
vative, the updated ICERs were relatively consistent with our
original estimate of $43,300 per QALY. Periodically updating
cost-effectiveness analyses should be a routine practice in cases
where ongoing survival data are collected. Even with 5 years of
data, most of the expected survival beneﬁt has yet to be observed.
CN4
PSYCHOMETRIC VALIDATION OF A PATIENT SYMPTOM
ASSESSMENT-LUNG CANCER (PSALC) INSTRUMENT FOR
SMALL CELL LUNG CANCER (SCLC)
Chen L1, Duh M1,Antras L1, Neary MP2, O’Brien ME3
1Analysis Group, Inc, Boston, MA, USA, 2GlaxoSmithKline, Collegeville,
PA, USA, 3Royal Marsden Hospital, Sutton, UK
OBJECTIVES: The PSALC is an instrument that was developed
for use in patients with SCLC for assessment of nine symptoms
(i.e., shortness of breath, cough, chest pain, hemoptysis, appetite
loss, sleep interference, hoarseness, fatigue, interference with
daily activities) scored on a scale from 1 (not at all) to 4 (very
much), but it has not been formally validated. METHODS: A
retrospective psychometric validation was conducted using data
from a randomized multicenter trial in which 107 patients with
SCLC were treated with intravenous topotecan and 104 patients
with cyclophosphamide, doxorubicin, and vincristine. PSALC
was administered to patients at baseline and at each of the four
subsequent clinical visits at 3-week intervals. Factor analysis
(FA), internal consistency, construct validity, reliability, and
responsiveness were evaluated. RESULTS: Baseline FA (n = 137)
indicated that there was only one factor, so the PSALC total score
was used for validation. Weighted Cronbach’s alpha from all
visits was 0.74 showing an acceptable internal consistency. 
Construct validity was supported by the high correlation with
established measures, with lower baseline PSALC total scores
associated with better Eastern Cooperative Oncology Group
(ECOG) performance status (12.41, 18.24, and 20.33 for ECOG
score = 0, 1, and 2, respectively, p < 0.0001; regression slope esti-
mate = 3.84, p < 0.0001; n = 135). Reliability was supported by
an intraclass correlation coefﬁcient of 0.61, calculated using
PSALC total scores evaluated before any change in clinical
status, and a concordance correlation coefﬁcient of 0.72, calcu-
lated using PSALC total scores at baseline and before the ﬁrst
visit. The PSALC total score was responsive to tumor progres-
sion (responsiveness statistic = 0.64; n = 33). CONCLUSION: A
retrospective analysis suggests that the PSALC is a reliable, valid,
and responsive instrument for measuring SCLC symptoms. If
feasible in this population, a prospective validation study could
be used to further evaluate these ﬁndings.
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OBJECTIVES: To evaluate trends in epoetin alfa (EPO) and 
darbepoetin alfa (DARB) dosing patterns and drug costs from
2005–2006 in elderly patients with pre-dialysis chronic kidney
disease (CKD) receiving care in nephrology clinics. METHODS:
A random panel of approximately 250 nephrologists was
requested to review the medical records of their two most
recently seen anemic pre-dialysis CKD patients who were receiv-
